Tg(Ins2-Chrm3*)SJwe
Transgene Detail
|
|
| Symbol: |
Tg(Ins2-Chrm3*)SJwe |
| Name: |
transgene insertion S, Jurgen Wess |
| MGI ID: |
MGI:5766547 |
| Synonyms: |
beta-R-s Tg |
| Transgene: |
Tg(Ins2-Chrm3*)SJwe Location: unknown
|
| Alliance: |
Tg(Ins2-Chrm3*)SJwe page
|
|
|
|
| Transgene Type: |
|
Transgenic (Inserted expressed sequence) |
| Mutation: |
|
Insertion
|
| |
|
Tg(Ins2-Chrm3*)SJwe expresses
1 gene
Transgene expresses:
| Organism |
Expressed Gene |
Note |
| Not Specified |
Chrm3 |
rat/turkey fusion |
|
| |
|
Tg(Ins2-Chrm3*)SJwe expression driven by
1 gene
Transgene expression driven by:
| Organism |
Driver Gene |
Homolog in Mouse |
Note |
| rat |
Ins2 (24506) |
|
|
|
| |
|
Mutation details: The transgene was designed to have (from 5' to 3') a 650 bp rat insulin 2 (Ins2; RIP II) promoter fragment, a hemagglutinin epitope tag (HA), the GsD coding sequence (R-s; described below), and untranslated human growth hormone sequences (containing transcriptional termination, polyadenylation and splicing signals). The GsD sequence is a Galpha>s<-coupled rat M3 DREADD (designer receptor exclusively activated by designer drug). To create the rM3Ds sequence, the wildtype rat muscarinic 3 receptor (Chrm3; M3R) sequence was first modified to replace the second and third intracellular loops with the corresponding turkey beta1-adrenergic receptor (ADRB1 or beta1AR) sequences. The second modification introduced, via site-directed mutagenesis, the Y148C and A238G amino acid substitutions that abolish receptor affinity for the native ligand, acetylcholine (ACh), but allow receptor binding and subsequent activation by the small drug-like molecule clozapine-N-oxide (CNO).
(J:154657)
|
|
|
| Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
| Carrying this Mutation: |
Mouse Strains: 1 strain available
Cell Lines: 0 lines available
|
|
| Original: |
J:154657 Guettier JM, et al., A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19197-202 |
| All: |
1 reference(s) |
|